Cyclerion Therapeutics (CYCN) Announces Departure of Chief Medical Officer

March 18, 2021 5:02 PM EDT
Get Alerts CYCN Hot Sheet
Price: $2.78 --0%

Overall Analyst Rating:
    NEUTRAL (= Flat)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Christopher Wright, M.D., Ph.D., Chief Medical Officer, has resigned his position with the company. He will provide Cyclerion with transitional support until March 26, 2021 and will join the Company’s Clinical Advisory Board.

“Chris has played an important role in advancing our clinical efforts, and we are pleased to have him join our Clinical Advisory Board. We wish Chris the very best in his future endeavors,” said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Changes, Management Comments

Related Entities